专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009045753A1 TRIAZOLOPYRIDINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS 审中-公开
标题翻译：三唑基吡啶11-羟基甾体脱氢酶I型抑制剂
公开(公告)号：WO2009045753A1
公开(公告)日：2009-04-09
申请号：PCT/US2008/076984
申请日：2008-09-19
申请人： BRISTOL-MYERS SQUIBB COMPANY , LI, Jun , ROBL, Jeffrey A. , LI, James J. , KENNEDY, Lawrence J. , WANG, Haixia , LI, Jie Jack , QIAN, Xinhua , DESHPANDE, Rajendra P. , KOLLA, Laxma R. , CANN, Reginald O. , WEI, Chenkou , GALELLA, Michael
发明人： LI, Jun , ROBL, Jeffrey A. , LI, James J. , KENNEDY, Lawrence J. , WANG, Haixia , LI, Jie Jack , QIAN, Xinhua , DESHPANDE, Rajendra P. , KOLLA, Laxma R. , CANN, Reginald O. , WEI, Chenkou , GALELLA, Michael
IPC分类号： C07D471/04 , A61K31/437 , A61P3/10 , A61P19/02
CPC分类号： C07D471/04
摘要： Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds of formula I: or stereoisomers or pharmaceutically acceptable salts thereof, wherein G, Q, X, Y, R 3 , R 3a , and R 3b are defined herein.
摘要翻译：提供了新的化合物，其为11-β-羟基类固醇脱氢酶I型抑制剂。 11-β-羟基类固醇脱氢酶I型抑制剂可用于治疗，预防或减缓需要11-β-羟基类固醇脱氢酶I型抑制剂治疗的疾病进展。这些新颖的式I化合物或其立体异构体或其药学上可接受的盐，其中G，Q，X，Y，R 3，R 3a和R 3b在本文中定义。

2. 发明申请

WO2008024892A3 CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS 审中-公开
标题翻译：循环11-羟基脱氢酶脱氢酶I型抑制剂
公开(公告)号：WO2008024892A3
公开(公告)日：2008-12-11
申请号：PCT/US2007076593
申请日：2007-08-23
申请人： SQUIBB BRISTOL MYERS CO , YE XIANG-YANG , ROBL JEFFREY A , HANSON RONALD L , GUO ZHIWEI , PATEL RAMESH N
发明人： YE XIANG-YANG , ROBL JEFFREY A , HANSON RONALD L , GUO ZHIWEI , PATEL RAMESH N
IPC分类号： C07C61/39 , C07C57/00 , C07C59/00 , C07C61/40 , C07C62/38 , C07D203/18 , C07D205/04 , C07D205/08 , C07D263/04 , C07D263/30 , C07D295/18 , C07D317/72 , C07D451/02 , C07D493/08
CPC分类号： C07C61/40 , C07B2200/07 , C07C57/50 , C07C57/62 , C07C59/54 , C07C59/56 , C07C59/72 , C07C59/88 , C07C61/39 , C07C62/38 , C07C2603/66 , C07C2603/74 , C07D203/18 , C07D205/04 , C07D205/06 , C07D207/12 , C07D207/14 , C07D207/16 , C07D211/42 , C07D211/46 , C07D213/40 , C07D217/02 , C07D241/08 , C07D257/04 , C07D261/02 , C07D261/08 , C07D263/04 , C07D277/04 , C07D277/46 , C07D277/64 , C07D277/82 , C07D285/135 , C07D295/185 , C07D295/205 , C07D401/12 , C07D403/04 , C07D407/06 , C07D413/04 , C07D471/04 , C07D493/08
摘要： Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-Beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure (I) enantiomers, diastereomers, solvates, or salts thereof, wherein A, W, X and Z are defined herein.
摘要翻译：提供了新的化合物，其为11-β-羟基类固醇脱氢酶I型抑制剂。 11-β-羟基类固醇脱氢酶I型抑制剂可用于治疗，预防或减缓需要11-β-羟基类固醇脱氢酶I型抑制剂治疗的疾病进展。这些新化合物具有其结构（I）对映异构体，非对映体，溶剂合物或其盐，其中A，W，X和Z如本文所定义。

3. 发明申请

WO2008005910A3 PYRIDONE/HYDROXYPYRIDINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS 审中-公开
标题翻译：吡啶酮/羟基吡啶11-β羟基类固醇脱氢酶I型抑制剂
公开(公告)号：WO2008005910A3
公开(公告)日：2008-03-20
申请号：PCT/US2007072626
申请日：2007-07-02
申请人： SQUIBB BRISTOL MYERS CO , ROBL JEFFREY A , WU SHUNG C , YOON DAVID S
发明人： ROBL JEFFREY A , WU SHUNG C , YOON DAVID S
IPC分类号： C07D217/24 , A61K31/4355 , A61P3/00 , C07D221/04 , C07D401/12 , C07D405/12 , C07D417/12 , C07D453/00 , C07D471/04
CPC分类号： C07D217/24 , C07D221/04 , C07D401/12 , C07D405/12 , C07D417/12 , C07D453/00 , C07D471/04
摘要： Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure formula (I) enantiomers, diastereomers, solvates, salts, tautomers or prodrugs thereof wherein, A, W, X, Y and R 1 are defined herein.
摘要翻译：提供了11-β-羟基类固醇脱氢酶I型抑制剂的新型化合物。 11-β-羟基类固醇脱氢酶I型抑制剂可用于治疗，预防或减缓需要11-β-羟基类固醇脱氢酶I型抑制剂治疗的疾病的进展。这些新型化合物具有结构式（I）的对映异构体，非对映异构体，溶剂合物，盐，互变异构体或前药，其中A，W，X，Y和R 1如本文所定义。

4. 发明申请

WO0196311A3 HMG-COA REDUCTASE INHIBITORS AND THEIR USE AS MEDICAMENTS FOR THE TREATMENT OF CHOLESTEROL RELATED DISEASES 审中-公开
标题翻译： HMG-COA还原抑制剂及其作为治疗胆固醇相关疾病的药物使用
公开(公告)号：WO0196311A3
公开(公告)日：2002-07-11
申请号：PCT/US0118868
申请日：2001-06-12
申请人： SQUIBB BRISTOL MYERS CO , ROBL JEFFREY A , CHEN BANG-CHI , SUN CHONG-QING
发明人： ROBL JEFFREY A , CHEN BANG-CHI , SUN CHONG-QING
IPC分类号： A61K31/435 , A61K31/438 , A61K31/473 , A61P1/00 , A61P1/04 , A61P1/16 , A61P3/04 , A61P3/06 , A61P3/10 , A61P7/02 , A61P9/00 , A61P9/08 , A61P9/10 , A61P9/12 , A61P15/10 , A61P19/08 , A61P19/10 , A61P25/28 , A61P29/00 , A61P31/18 , A61P35/00 , A61P43/00 , C07D221/08 , C07D221/10 , C07D221/16 , C07D221/20 , C07D405/06 , C07D221/06 , C07D221/18
CPC分类号： C07D221/20 , C07D221/10 , C07D221/16 , C07D405/06
摘要： Compounds of the following structure are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, dyslipidemia, hormone replacement therapy, hypercholesterolemia, hypertriglyceridemia and atherosclerosis as well as Alzheimer's disease and osteoporosis (Formula (I)) and pharmaceutically acceptable salts thereof, Z is Formula (a) or Formula (b); n is 0 or 1; x is 0, 1, 2, 3 or 4; y is 0, 1, 2, 3 or 4, provided that at least one of x and y is other than 0; and optionally one or more carbons of (CH2)x and/or (CH2)y together with additional carbons form a 3 to 7 membered spirocyclic ring; R1 and R2 are the same or different and are independently selected from alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl or cycloheteroalkyl; R3 is H or lower alkyl; R4 and R7 are as defined herein.
摘要翻译：以下结构的化合物是HMG CoA还原酶抑制剂，因此具有抑制胆固醇生物合成，调节血清脂质的作用，例如降低LDL胆固醇和/或增加HDL胆固醇，以及治疗高脂血症，血脂异常，激素替代疗法，高胆固醇血症，高甘油三酯血症动脉粥样硬化以及阿尔茨海默氏病和骨质疏松症（式（I））及其药学上可接受的盐，Z为式（a）或式（b）; n为0或1; x为0,1,2,3或4; y为0,1,2,3或4，条件是x和y中的至少一个不为0; 和任选的（CH 2）x和/或（CH 2）y的一个或多个碳与另外的碳一起形成3至7元的螺环; R 1和R 2相同或不同，并且独立地选自烷基，芳基烷基，环烷基，烯基，环烯基，芳基，杂芳基或环杂烷基; R3是H或低级烷基; R4和R7如本文所定义。

5. 发明申请

WO2008024892A2 CYCLIC 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS 审中-公开
标题翻译：环状11-β羟基类固醇脱氢酶I型抑制剂
公开(公告)号：WO2008024892A2
公开(公告)日：2008-02-28
申请号：PCT/US2007/076593
申请日：2007-08-23
申请人： BRISTOL-MYERS SQUIBB COMPANY , YE, Xiang-yang , ROBL, Jeffrey A. , HANSON, Ronald L. , GUO, Zhiwei , PATEL, Ramesh N.
发明人： YE, Xiang-yang , ROBL, Jeffrey A. , HANSON, Ronald L. , GUO, Zhiwei , PATEL, Ramesh N.
IPC分类号： C07C57/50 , C07C57/62 , C07C59/56 , C07C59/72 , C07C59/88 , C07C61/39 , C07C61/40 , C07C59/54 , C07D203/18 , C07D205/04 , C07D205/08 , C07D263/04
CPC分类号： C07C61/40 , C07B2200/07 , C07C57/50 , C07C57/62 , C07C59/54 , C07C59/56 , C07C59/72 , C07C59/88 , C07C61/39 , C07C62/38 , C07C2603/66 , C07C2603/74 , C07D203/18 , C07D205/04 , C07D205/06 , C07D207/12 , C07D207/14 , C07D207/16 , C07D211/42 , C07D211/46 , C07D213/40 , C07D217/02 , C07D241/08 , C07D257/04 , C07D261/02 , C07D261/08 , C07D263/04 , C07D277/04 , C07D277/46 , C07D277/64 , C07D277/82 , C07D285/135 , C07D295/185 , C07D295/205 , C07D401/12 , C07D403/04 , C07D407/06 , C07D413/04 , C07D471/04 , C07D493/08
摘要： Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-Beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure (I) enantiomers, diastereomers, solvates, or salts thereof, wherein A, W, X and Z are defined herein.
摘要翻译：提供了新型化合物，其是11-β-羟基类固醇脱氢酶I型抑制剂。 11-β-羟基类固醇脱氢酶I型抑制剂可用于治疗，预防或减缓需要11-β-羟基类固醇脱氢酶I型抑制剂治疗的疾病的进展。这些新化合物具有结构（I）对映异构体，非对映异构体，溶剂化物或盐，其中A，W，X和Z如本文所定义。

6. 发明申请

WO2007103694A3 TRIAZINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS 审中-公开
公开(公告)号：WO2007103694A3
公开(公告)日：2007-09-13
申请号：PCT/US2007/063012
申请日：2007-03-01
申请人： BRISTOL-MYERS SQUIBB COMPANY , LI, Jun , ROBL, Jeffrey A. , KENNEDY, Lawrence J.
发明人： LI, Jun , ROBL, Jeffrey A. , KENNEDY, Lawrence J.
IPC分类号： C07D253/06 , C07D253/08 , A61K31/53 , A61P5/46
摘要： Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 and R 3 are defined herein.

7. 发明申请

WO2012149236A1 NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS 审中-公开
标题翻译：新型双相含氮异氰酸酯TGR5受体调节剂
公开(公告)号：WO2012149236A1
公开(公告)日：2012-11-01
申请号：PCT/US2012/035327
申请日：2012-04-27
申请人： BRISTOL-MYERS SQUIBB COMPANY , ROBL, Jeffrey A. , LI, Jun , KENNEDY, Lawrence J. , WALKER, Steven J. , WANG, Haixia , WASHBURN, William N. , AHMAD, Saleem , NGU, Khehyong
发明人： ROBL, Jeffrey A. , LI, Jun , KENNEDY, Lawrence J. , WALKER, Steven J. , WANG, Haixia , WASHBURN, William N. , AHMAD, Saleem , NGU, Khehyong
IPC分类号： C07D215/08 , C07D401/04 , C07D403/04 , C07D413/04 , C07D417/04 , A61K31/4709 , A61K31/553 , A61K31/554 , A61P3/00 , A61P9/00 , C07D401/14 , C07D413/14
CPC分类号： C07D401/04 , A61K31/47 , A61K31/4709 , A61K31/473 , A61K31/4747 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/5415 , A61K31/55 , A61K31/553 , A61K31/554 , A61K31/675 , A61K45/06 , C07D215/08 , C07D221/16 , C07D401/12 , C07D401/14 , C07D403/04 , C07D405/14 , C07D409/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07F9/60
摘要： Novel compounds of Formula I:or an enantiomer, diastereomer, tautomer, prodrug or salt thereof, wherein m, Q, T, U, V, ring A, X, Y, R 3 , R 4 , R 4a , R 5a , R 5b , R 5c , R 5d , R 5e , R 6a , R 6b , and R 6c are defined herein, are provided which are TGR5 G protein-coupled receptor modulators. TGR5 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring TGR5 G protein-coupled receptor modulator therapy. Thus, the disclosure also concerns compositions comprising these novel compounds and methods of treating diseases or conditions related to the activity of the TGR5 G protein-coupled receptor by using any of these novel compounds or a composition comprising any of such novel compounds.
摘要翻译：式I的新型化合物或其对映体，非对映体，互变异构体，前药或其盐，其中m，Q，T，U，V，环A，X，Y，R 3，R 4，R 4a，R 5a，R 5b，R 5c，本文定义的R5e，R6a，R6b和R6c是TGR5G蛋白偶联受体调节剂。 TGR5G蛋白偶联受体调节剂可用于治疗，预防或减缓需要TGR5G蛋白偶联受体调节剂治疗的疾病进展。因此，本公开还涉及包含这些新化合物的组合物和通过使用任何这些新化合物或包含任何这些新化合物的组合物来治疗与TGR5G蛋白偶联受体的活性有关的疾病或病症的方法。

8. 发明申请

WO2010104830A1 PYRIDONE ANALOGS USEFUL AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS 审中-公开
标题翻译：吡咯烷酮类似物有效用于浓缩HORMONE受体-1拮抗剂的MELANIN
公开(公告)号：WO2010104830A1
公开(公告)日：2010-09-16
申请号：PCT/US2010/026626
申请日：2010-03-09
申请人： BRISTOL-MYERS SQUIBB COMPANY , AHMAD, Saleem , WASHBURN, William, N. , HERNANDEZ, Andres, S. , ROBL, Jeffrey, A. , NGU, Khehyong , WANG, Zhenghua
发明人： AHMAD, Saleem , WASHBURN, William, N. , HERNANDEZ, Andres, S. , ROBL, Jeffrey, A. , NGU, Khehyong , WANG, Zhenghua
IPC分类号： A61K31/4412 , A61P3/04 , C07D213/38 , C07D213/74 , C07D213/30 , C07D213/32 , C07D213/26 , C07D213/68 , C07D401/04 , A61K31/4409 , A61K31/4427
CPC分类号： C07D213/38 , A61K31/4412 , A61K31/4427 , C07D213/26 , C07D213/30 , C07D213/32 , C07D213/68 , C07D401/04
摘要： MCHR1 antagonists are provided having the following Formula I: wherein A 1 and A 2 are independently C or N; E is C or N; D 1 is a bond, -CR 8 R 9 X-, -XCR 8 R 9 -, -CHR 8 CHR 9 -, -CR 10 =CR 10' -, -C≡C-, or 1,2-cyclopropyl; X is O, S or -NR 11 ; R 1 , R 2 , and R 3 are independently selected from the group consisting of hydrogen, halogen, lower alkyl, lower cycloalkyl, lower cycloalkoxy, -CF 3 , -OCF 3 , -OR 12 and -SR 12 ; G is O or S; D 2 is lower alkyl, lower cycloalkyl, lower alkylcycloalkyl, lower cycloalkylalkyl, lower cycloalkoxyalkyl or lower alkycycloalkoxy; Z 1 and Z 2 are independently hydrogen, halogen, lower alkyl, lower cycloalkyl, lower alkoxy, lower cycloalkoxy, halo, -CF 3 , -OCONR 14 R 14' , -CN, -CONR 14 R 14' , -SOR 12 , -SO 2 R 12 , -NR 14 COR 14' , -NR 14 CO 2 R 14' , -CO 2 R 12 , NR 14 SO 2 R 12 or -COR 12 provided that if Z 1 is -CH 3 and one of R 1 , R 2 , or R 3 is F, then Z 2 cannot be H;; R 5 , R 6 , and R 7 are independently selected from the group consisting of hydrogen, halogen, lower alkyl, lower cycloalkyl, -CF 3 , -SR 12 , lower alkoxy, lower cycloalkoxy, -OCH 2 OMe, -CN, -CONR 14 R 14' , SOR 12 , SO 2 R 12 , NR 14 COR 14' , NR 14 CO 2 R 12 , CO 2 R 12 , NR 14 SO 2 R 12 and -COR 12 ; R 8 , R 9 , R 10 , R 10' , R 11 are independently hydrogen or lower alkyl; R 12 is lower alkyl or lower cycloalkyl; and R 14 and R 14' are independently H, lower alkyl, lower cycloalkyl or R 14 and R 14' together with the N to which they are attached form a ring having 4 to 7 atoms. Such compounds are useful for the treatment of MCHR1 mediated diseases, such as obesity, diabetes, IBD, depression, and anxiety.
摘要翻译：提供具有下式I的MCHR1拮抗剂：其中A1和A2独立地为C或N; E为C或N; D1是键，-CR8R9X-，-XCR8R9-，-CHR8CHR9-，-CR10 = CR10'-，-C = C-或1,2-环丙基; X是O，S或-NR 11; R 1，R 2和R 3独立地选自氢，卤素，低级烷基，低级环烷基，低级环烷氧基，-CF 3，-OCF 3，-OR 12和-SR 12; G为O或S; D2是低级烷基，低级环烷基，低级烷基环烷基，低级环烷基烷基，低级环烷氧基烷基或低级烷基环烷氧基; Z1和Z2独立地是氢，卤素，低级烷基，低级环烷基，低级烷氧基，低级环烷氧基，卤素，-CF3，-OCONR14R14'，-CN，-CONR14R14'，-SOR12，-SO2R12，-NR14COR14'，-NR14CO2R14' ，-CO 2 R 12，NR 14 SO 2 R 12或-COR 12，条件是如果Z 1是-CH 3并且R 1，R 2或R 3中的一个是F，则Z 2不能是H。 R5，R6和R7独立地选自氢，卤素，低级烷基，低级环烷基，-CF3，-SR12，低级烷氧基，低级环烷氧基，-OCH2OMe，-CN，-CONR14R14'，SOR12，SO2R12， NR14COR14'，NR14CO2R12，CO2R12，NR14SO2R12和-COR12; R8，R9，R10，R10'，R11独立地为氢或低级烷基; R12是低级烷基或低级环烷基; 并且R 14和R 14'独立地为H，低级烷基，低级环烷基或R 14和R 14'与它们所连接的N一起形成具有4至7个原子的环。这些化合物可用于治疗MCHR1介导的疾病，例如肥胖症，糖尿病，IBD，抑郁症和焦虑症。

9. 发明申请

WO2005030758A1 PYRIMIDINE AND PYRIDINE DERIVATIVES USEFUL AS HMG-COA REDUCTASE INHIBITORS AND METHOD OF PREPARATION THEREOF 审中-公开
标题翻译：用作HMG-COA还原酶抑制剂的吡嗪和吡啶衍生物及其制备方法
公开(公告)号：WO2005030758A1
公开(公告)日：2005-04-07
申请号：PCT/US2004/031212
申请日：2004-09-22
申请人： BRISTOL-MYERS SQUIBB COMPANY , AHMAD, Saleem , ROBL, Jeffrey, A. , NGU, Khehyong
发明人： AHMAD, Saleem , ROBL, Jeffrey, A. , NGU, Khehyong
IPC分类号： C07D403/12
CPC分类号： C07D213/74 , C04B35/632 , C07D239/42 , C07D401/12 , C07D403/12 , C07D413/12 , C07D417/12
摘要： Compounds are provided having the following structure which are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, dyslipidemia, hormone replacement therapy, hypercholsterolemia, hypertriglyceridemia and atherosclerosis as well as Alzheimer's disease and osteoporosis identified in Formula (I) wherein X is N or CR 5 ; and pharmaceutically acceptable salts thereof, Z is identified in Formula (II) or in Formula (III) ; wherein R 1 to R 7 are as defined herein. A method for treating the above diseases employing the above compounds is also provided.
摘要翻译：提供具有以下结构的化合物，其为HMG CoA还原酶抑制剂，因此具有抑制胆固醇生物合成，调节血清脂质，例如降低LDL胆固醇和/或增加HDL胆固醇，以及治疗高脂血症，血脂异常，激素替代疗法，高胆固醇血症，高甘油三酯血症和动脉粥样硬化以及式（I）中鉴定的阿尔茨海默病和骨质疏松症，其中X是N或CR5; Z在式（II）或式（III）中鉴定; 其中R 1至R 7如本文所定义。还提供了使用上述化合物治疗上述疾病的方法。

10. 发明申请

WO2003011824A1 BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION 审中-公开
标题翻译：雄激素受体功能的双相调制剂
公开(公告)号：WO2003011824A1
公开(公告)日：2003-02-13
申请号：PCT/US2002/024185
申请日：2002-07-31
申请人： BRISTOL-MYERS SQUIBB COMPANY , SUN, Chongqing , ROBL, Jeffrey, A. , SALVATI, Mark, E. , WANG, Tammy , HAMANN, Lawrence , AUGERI, David
发明人： SUN, Chongqing , ROBL, Jeffrey, A. , SALVATI, Mark, E. , WANG, Tammy , HAMANN, Lawrence , AUGERI, David
IPC分类号： C07D207/09
CPC分类号： C07D207/16 , C07D471/04 , C07D487/04 , C07D513/04
摘要： The invention provides compounds of the formula I [INSERT CHEMICAL STRUCTURE HERE]wherein the substitutents are as described herein. Further provided are methods of using such compounds for the treatment of nuclear hormone receptor-associated conditions, such as age related diseases, for example sarcopenia, and also provided are pharmaceutical compositions containing such compounds.
摘要翻译：本发明提供了式I化合物[其中化学结构如此），其中取代基如本文所述。还提供了使用这些化合物治疗核激素受体相关病症（如与年龄相关的疾病，例如肌肉减少症）的方法，并且还提供含有这些化合物的药物组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式